Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Rises By 20.9%

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 82,140 shares, a growth of 20.9% from the January 29th total of 67,935 shares. Based on an average daily volume of 51,786 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.7% of the company’s shares are short sold. Currently, 1.7% of the company’s shares are short sold. Based on an average daily volume of 51,786 shares, the days-to-cover ratio is currently 1.6 days.

Evaxion A/S Stock Down 0.6%

Shares of NASDAQ:EVAX traded down $0.02 during midday trading on Thursday, reaching $3.09. The company’s stock had a trading volume of 33,495 shares, compared to its average volume of 53,348. The firm has a 50 day moving average of $3.97 and a 200-day moving average of $4.61. The firm has a market capitalization of $25.77 million, a P/E ratio of -7.92 and a beta of 0.28. Evaxion A/S has a 12-month low of $1.20 and a 12-month high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last announced its earnings results on Thursday, March 5th. The company reported $0.30 earnings per share for the quarter. On average, research analysts predict that Evaxion A/S will post -0.15 EPS for the current year.

Hedge Funds Weigh In On Evaxion A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S in the fourth quarter worth $72,000. Wesbanco Bank Inc. purchased a new position in Evaxion A/S in the 4th quarter worth about $48,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S during the 4th quarter valued at about $38,000. 11.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EVAX has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Maxim Group started coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.75.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.